Metastatic CRC patients with BRAF mutant tumours are characterised by poor response rates to the anti-EGFR monoclonal antibodies (moAb) panitumumab and cetuximab and poor prognosis, with a median overall survival of only about 9 to 12 months. The gene discussed is BRAF; the disease is neoplasm.